FDA Approves Unknown Drug — SANDOZ

**FDA** has granted final approval to **SANDOZ** for the **ANDA209710**, a generic submission indicating the company is poised to capture market share as the patent exclusivity for the branded reference product expires. This launch is anticipated to trigger price erosion in the therapeutic class, significantly increasing competitive intensity in the sector.